NanoMab   Report issue

For profit Phase 1
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT04040686
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NanoMab